Price
CHART BY
Frequently asked questions
What is Novocure's market capitalization?
The market capitalization of Novocure is $3.33B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Novocure?
Novocure's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.394. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Novocure's stock?
Currently, 7 analysts cover Novocure's stock, with a consensus target price of $35.00. Analyst ratings provide insights into the stock's expected performance.
What is Novocure's revenue over the trailing twelve months?
Over the trailing twelve months, Novocure reported a revenue of $577.74M.
What is the EBITDA for Novocure?
Novocure's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$139.34M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Novocure?
Novocure has a free cash flow of -$78.21M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Novocure have, and what sector and industry does it belong to?
Novocure employs approximately 1,453 people. It operates in the Health Care sector, specifically within the Medical Specialties industry.
What is the free float of Novocure's shares?
The free float of Novocure is 97.35M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $3.33B
- EPS (TTM)
- -$1.394
- Free Float
- 97.35M
- Revenue (TTM)
- $577.74M
- EBITDA (TTM)
- -$139.34M
- Free Cashflow (TTM)
- -$78.21M
Pricing
- 1D span
- $29.66$31.49
- 52W span
- $11.70$34.08
Analyst Ratings
The price target is $35.00 and the stock is covered by 7 analysts.
Buy
5
Hold
2
Sell
0
Information
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
- Employees
- 1,453
- Industries
- Medical Specialties
- Sector
- Health Care
Identifier
- ISIN
- JE00BYSS4X48
- Primary Ticker
- NVCR